World Journal of Urology最新文献

{"title":"Association of molecular subtypes based on GATA3, KRT5, and P16 expression with clinicopathological features and prognosis in upper tract urothelial carcinoma.","authors":"Jiayu Yang, Wentao Yu, Shengwang Zhang, Qian Chen","doi":"10.1007/s00345-026-06854-8","DOIUrl":"10.1007/s00345-026-06854-8","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to classify upper tract urothelial carcinoma (UTUC) using GATA3, KRT5, and P16 immunohistochemistry and to evaluate associations of these molecular subtypes with clinicopathological features and outcomes.</p><p><strong>Patients/materials and methods: </strong>Tissue samples from 102 UTUC patients who underwent radical nephroureterectomy were analyzed. Tumors were classified into genomically unstable (GU), urothelial-like (URO), and basal subtypes based on GATA3, KRT5, and P16 expression. Associations with pathological features, recurrence, and survival were analyzed. Kaplan-Meier and Cox regression analyses were used.</p><p><strong>Results: </strong>The GU, URO, and basal subtypes accounted for 33%, 45%, and 22% of cases, respectively. Subtype was significantly associated with infiltrative pattern (p = 0.009), perineural invasion (p = 0.016), histological variant (p < 0.001), T stage (p = 0.004), N stage (p = 0.017), and vital status (p = 0.005). The basal subtype showed the poorest prognosis, with 3-year overall survival of 41% vs. 85% for the URO subtype (p < 0.001). Multivariable analysis identified diffuse infiltrative pattern (HR 6.84, P = 0.004), lymphovascular invasion (HR 2.12, p = 0.046), and T4 stage (HR 9.80, p = 0.023) as independent risk factors for overall survival, and diffuse infiltrative pattern (HR 6.37, p = 0.006) and T4 stage (HR 12.6, p = 0.012) for recurrence-free survival.</p><p><strong>Conclusions: </strong>IHC-based subtyping using GATA3, KRT5, and P16 is significantly associated with aggressive clinicopathological features in UTUC, with the basal subtype showing poor prognosis in univariate analysis. However, it was not an independent prognostic factor in multivariable analysis. While this exploratory strategy may aid in risk stratification, its clinical utility requires further validation in larger, prospective cohorts.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparator purity and study-set composition in the comparison of ThuFLEP with conventional HoLEP.","authors":"Ting Ye","doi":"10.1007/s00345-026-06827-x","DOIUrl":"10.1007/s00345-026-06827-x","url":null,"abstract":"","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Female stress urinary incontinence surgical trends in New Zealand from 2010 to 2025: before and after a mesh pause and national surgeon credentialing.","authors":"Eva Fong, Michael Keane, Sum Sum Lo, Giovanni Losco, Hazel Ecclestone","doi":"10.1007/s00345-026-06812-4","DOIUrl":"10.1007/s00345-026-06812-4","url":null,"abstract":"<p><strong>Objectives: </strong>To examine trends in surgical management of female stress urinary incontinence (SUI) from 2010 to 2025 including the impact of the mesh pause of August 2023 and national credentialing of surgeons.</p><p><strong>Methods: </strong>This retrospective cohort study used the Health New Zealand National Minimum Dataset (hospital events, NMDS). This includes all publicly funded hospital events from 2010-2025 for female stress urinary incontinence procedures being: mesh slings, fascial slings, Colposuspension and periurethral bulking agents.</p><p><strong>Results: </strong>There was significant and sustained decline in female SUI procedures beginning in 2013 to 2022. There was also a shift in procedural types with mesh slings being the predominant procedure before 2020 and periurethral bulking agents increasing from 2017. Following the mesh pause, there was no change in overall SUI activity prior to and after the pause. However, there was shift in the predominant procedures from mesh slings to periurethral bulking agents. In younger age groups the fall in sling procedures and increase in bulking was more marked. In the context of surgeon credentialing which began in 2022 through till october 2025, we found 64% of Colposuspensions and 22% of fascial slings were performed at a hospital without a New Zealand framework credentialled surgeon. Due to NMDS database being hospital/procedural based, we assigned credentialing at hospital level which may overestimate the availability of credentialled expertise at the hospital level.</p><p><strong>Conclusion: </strong>Between 2010 to 2025, there has been a sustained decline in female SUI procedures in New Zealand public hospitals. This decline began in 2013, nine years before the mesh pause of 2023. There has been a significant shift in the predominant SUI procedures following the mesh pause from highly efficacious procedures, mesh slings, to periurethral bulking agents, which are less efficacious. We also found that following credentialing, a significant proportion of procedures were performed in hospitals without a credentialed surgeon.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Cormio A, Gauhar V, Herrmann T, et al. Influence of intraoperative tranexamic acid on bleeding outcomes in patients receiving antithrombotic therapy undergoing endoscopic enucleation of the prostate: a multicenter prospective study by the endourology section of EAU. World J Urol. 2026;44:179.","authors":"Edoardo Pozzi, Vincenzo Scattoni, Andrea Salonia, Alberto Briganti, Francesco Montorsi","doi":"10.1007/s00345-026-06823-1","DOIUrl":"10.1007/s00345-026-06823-1","url":null,"abstract":"","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to correspondence on perioperative monitoring during thulium laser prostate enucleation.","authors":"Philipp Kuhn, Thomas Wieser, JoEllen Welter, Roman Rechner, Jan T Klein, Thomas R W Herrmann, Alexander Dullenkopf","doi":"10.1007/s00345-026-06838-8","DOIUrl":"10.1007/s00345-026-06838-8","url":null,"abstract":"","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of ureteral stenting on the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors involving the ureteral orifice.","authors":"Nikolaos Pyrgidis, Patrick Engelmann, Daniel Puhr-Westerheide, Benedikt Ebner, Marc Kidess, Marie Semmler, Patrick Keller, Christian Stief, Gerald Bastian Schulz, Yannic Volz","doi":"10.1007/s00345-026-06839-7","DOIUrl":"10.1007/s00345-026-06839-7","url":null,"abstract":"<p><strong>Background: </strong>Ureteral stenting in patients with bladder cancer involving the ureteral orifice may increase the rate of metachronous upper tract urothelial carcinoma (UTUC). Nevertheless, evidence on the matter is scarce and often contradictory.</p><p><strong>Materials and methods: </strong>We performed an observational study comparing ureteral stenting versus no stenting with respect to the risk of developing metachronous UTUC in patients who underwent transurethral resection of bladder tumors (TURBT) involving the ureteral orifice between January 2015 and December 2024. We performed time-to-event analyses to estimate hazard ratios (HRs) along with their corresponding 95% confidence intervals (CIs).</p><p><strong>Results: </strong>We included 151 patients with a median age of 73 years. 37 (25%) underwent ureteral stenting during TURBT. Patients undergoing stenting had higher BMI (p = 0.014), more aggressive tumors (p = 0.003), underwent prior intravesical therapy more often (p = 0.008), higher preoperative creatinine values (p = 0.007), and longer hospitalization duration (p = 0.002) compared to those who did not undergo stenting. After a median follow-up of 25 months, 8 patients developed metachronous UTUC (2 in the stenting group and 6 in the non-stenting group). Ureteral stenting was not associated with statistically significantly higher rates of metachronous UTUC (HR: 1.2, 95%CI: 0.31-5.6, p > 0.9). During follow-up, 49 (33%) patients developed recurrence in the bladder, 43 (28%) underwent cystectomy, and 24 (16%) died. The HRs did not significantly differ between the two groups.</p><p><strong>Conclusions: </strong>The present study did not demonstrate an increased risk of metachronous UTUC after stenting during TURBT with urothelial cancer involving the ureteral orifice. Moreover, stenting was not statistically significantly associated with increased recurrences in the urinary bladder, higher cystectomy rates, or worse mortality.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13638760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphocele After Radical Prostatectomy: A Systematic Review of Risk Factors and Quantitative Synthesis Preventive Strategies.","authors":"Ömer Faruk Çavdar, Burak Akgül, Furkan Güldibi, Bhaskar Somani, Karim Touijer, Alex de la Taille, Kamran Ahmed, Thomas Knoll, Thomas R W Herrman, Lütfi Tunç, Selçuk Güven","doi":"10.1007/s00345-026-06809-z","DOIUrl":"10.1007/s00345-026-06809-z","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to systematically evaluate the perioperative risk factors and preventive strategies associated with lymphocele formation and prolonged lymphatic drainage after radical prostatectomy with pelvic lymph node dissection, to assess the effect of peritoneal reconstruction techniques on symptomatic lymphocele reduction, and to provide an integrated clinical framework for evaluating etiological factors and preventive strategies.</p><p><strong>Materials and methods: </strong>A comprehensive search of Embase, MEDLINE (PubMed), and the Cochrane Library was performed through December 2025 according to PRISMA guidelines (PROSPERO ID: CRD420251164157). Thirty-one studies evaluating preoperative, intraoperative, and postoperative risk factors and preventive strategies were included. Risk of bias was assessed using RoB 2, ROBINS-I, and ROBINS-E tools. A primary meta-analysis of randomized controlled trials and a predefined sensitivity analysis including all comparative studies were conducted for symptomatic lymphocele (sLC) using random-effects models.</p><p><strong>Results: </strong>High BMI and selected metabolic parameters, including low fibrinogen and hypoalbuminemia, emerged as potential preoperative risk factors, although supporting evidence was limited and not consistently reported across studies. Peritoneal flap-based reconstruction significantly reduced symptomatic lymphocele in pooled randomized data (RR 0.57, 95% CI 0.35-0.95). A predefined sensitivity analysis including six comparative studies (n = 3840) suggested a larger effect (RR 0.18, 95% CI 0.09-0.37), although these findings should be interpreted cautiously because of potential confounding and heterogeneity across study designs and surveillance protocols. Preventive strategies such as peritoneal reconstruction and selective drain management were associated with reduced lymphatic complications, whereas octreotide and lymphatic embolization were effective management options for established or refractory lymphatic leakage.</p><p><strong>Conclusion: </strong>Lymphocele formation after radical prostatectomy is multifactorial. Restoration of peritoneal continuity appears to be the most consistent and modifiable strategy for reducing symptomatic lymphocele. These findings support a comprehensive, risk-adapted approach integrating patient- and procedure-related factors beyond isolated technical interventions and highlight the need for further multicenter randomized studies.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partial vs. whole-gland salvage hifu after radiotherapy failure: oncological and functional outcomes.","authors":"Cyriel Maillard, Samy Mebroukine, Thibaud Haaser, Gilles Pasticier, Grégoire Robert, Franck Bladou","doi":"10.1007/s00345-026-06831-1","DOIUrl":"10.1007/s00345-026-06831-1","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the long-term oncological and functional outcomes of whole-gland and partial-gland salvage high-intensity focused ultrasound (S-HIFU) in patients with radiorecurrent prostate cancer, for whom local recurrence after radiotherapy remains a major therapeutic challenge and radical salvage surgery is associated with substantial morbidity.</p><p><strong>Methods: </strong>We performed a retrospective single-center study including 138 patients treated with S-HIFU between August 2006 and October 2023 for biopsy-proven local recurrence without metastatic disease. Treatments consisted of whole-gland or partial-gland ablation, including hemi-gland and focal therapy. Oncological outcomes were assessed using Kaplan-Meier analyses and multivariable Cox regression models evaluating progression-free survival (PFS), metastasis-free survival (MFS), and cancer-specific survival (CSS). Postoperative complications were graded according to the Clavien-Dindo classification.</p><p><strong>Results: </strong>After a median follow-up of over five years, 5-year PFS, MFS, and CSS rates were 43.6%, 85%, and 95%, respectively. Higher pre-HIFU prostate-specific antigen (PSA) levels and ISUP grade ≥ 5 independently predicted disease progression. No significant differences in PFS or MFS were observed between whole-gland and partial-gland treatments. Acute urinary retention occurred in 33% of patients and voiding dysfunction in 39.9%, requiring surgical management in 34.1% of cases. Severe complications were significantly more frequent after whole-gland compared with partial-gland S-HIFU (48.3% vs. 29.8%, p < 0.05).</p><p><strong>Conclusion: </strong>S-HIFU represents a viable salvage option after radiotherapy failure. Our results support that partial-gland S-HIFU significantly reduces severe morbidity while maintaining comparable oncological outcomes compared to whole-gland S-HIFU in appropriately selected patients.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of magnetic resonance imaging-based diagnostic pathway on oncologic outcomes of localised prostate cancer between primary treatment modalities: a Will-Rogers phenomenon?","authors":"Lingyue Yu, Han Jie Lee, Alvin Yuanming Lee, Jia Ling Goh, Kae Jack Tay, Henry Sun Sien Ho, Jeffrey Tuan, John Shyi Peng Yuen, Kenneth Chen","doi":"10.1007/s00345-026-06844-w","DOIUrl":"10.1007/s00345-026-06844-w","url":null,"abstract":"<p><strong>Background: </strong>The MRI pathway (pre-biopsy MRI-targeted plus saturation biopsies, MRI-Bx) outperforms transrectal ultrasound systematic prostate biopsy (TRUS-Bx) in diagnosing clinically significant prostate cancer (csPCa). However, there is a dearth of data on how this paradigm shift influences biochemical recurrence (BCR)-free survival in patients after radical prostatectomy (RP) or radiotherapy (RT). We aim to evaluate BCR-free survival in the MRI-Bx era stratified by primary treatment modalities in a large contemporary cohort.</p><p><strong>Methods: </strong>We retrospectively reviewed localised prostate cancer patients diagnosed by MRI-Bx or TRUS-Bx and treated with RP or RT between 2010 and 2021. Patients diagnosed and staged by PSMA-PET were excluded. BCR was defined as two successive prostatic specific antigen (PSA) > 0.2 ng/mL after RP or a rise of 2 ng/mL from PSA nadir after RT within 3 years. Kaplan-Meier (KM) analyses and multivariable Cox proportional hazards regression were performed for BCR-free survival.</p><p><strong>Results: </strong>A total of 1674 men included (1061 RP, 613 RT; 1075 TRUS-Bx, 599 MRI-Bx; median follow-up 38 months). Across all risk group, MRI-Bx yielded higher BCR-free survival at all timepoints in RP patients, especially in high-risk disease (3-year: 85% vs. 71%). In RT patients, MRI-Bx yielded no significant difference across all timepoints. On multivariable regression, MRI-Bx approach independently predicted BCR in RP patients (hazard ratio (HR) 0.60, 95% CI 0.40-0.90, p = 0.013) but not in RT patients (HR 0.94, 95% CI 0.31-3.85, p = 0.945) after adjusting for age, PSA, clinical T stage, Gleason grade group, adjuvant ADT and EAU risk groups. In terms of GG concordance after RP, MRI-Bx demonstrated decreased GG upgrading than TRUS-Bx group (23.1% vs. 27.4%) but increased GG downgrading (20.6% vs. 14.4%), which was statistically significant (p = 0.025).</p><p><strong>Conclusions: </strong>Patients managed via the MRI pathway exhibited improved BCR-free survival following RP, reflecting a risk migration consistent with the Will-Rogers phenomenon. This survival advantage was attenuated in the RT cohort, potentially due to difference in BCR definition and adjuvant ADT use. The risk reclassification in the RP cohort after MRI pathway adoption underscores the necessity of new risk models integrating quantitative MRI parameters to better select patients for surgery. Longer follow-up is required to determine the impact on overall and cancer-specific survival.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.","authors":"Jihane Elmasmoudi, Axel S Merseburger","doi":"10.1007/s00345-026-06790-7","DOIUrl":"10.1007/s00345-026-06790-7","url":null,"abstract":"<p><strong>Purpose: </strong>To critically appraise circulating tumour DNA (ctDNA) and extrachromosomal DNA (ecDNA) in prostate and bladder cancer, and to define what evidence links the two.</p><p><strong>Methods: </strong>Narrative review of search period July-September 2026, supplemented by reference-list and citation screening, covering ctDNA and ecDNA biology, detection and clinical application in prostate and urothelial cancer. The ctDNA-ecDNA interface was appraised using a five-tier evidentiary framework (copy-number gain; structural rearrangement; amplicon-graph reconstruction; phasing/optical mapping; orthogonal validation).</p><p><strong>Results: </strong>In bladder cancer, the phase 3 IMvigor011 trial validated ctDNA-guided adjuvant atezolizumab (disease-free survival [DFS] HR 0.64; overall survival [OS] HR 0.59), while persistently ctDNA-negative patients had 2-year DFS/OS of 88.4%/97.1% without adjuvant therapy. In prostate cancer, ctDNA positivity and androgen-receptor alterations are strongly prognostic (median OS 29.0 vs. 47.4 months; HR 2.0), but no prospective ctDNA-guided interventional trial exists. ecDNA is present in approximately 36% of urothelial carcinomas and drives oncogene amplification, heterogeneity, immune evasion and resistance. Evidence linking the two is indirect and asymmetric: prostate cancer offers stronger longitudinal ctDNA evidence via plasma AR-ecDNA proxy signatures, whereas bladder cancer shows stronger structural evidence from urinary sediment; no structurally validated blood ecDNA has been reported. This evidence derives predominantly from metastatic cohorts (mCRPC, post-cystectomy bladder cancer), with no established role in earlier-stage or minimal-residual-disease settings.</p><p><strong>Conclusion: </strong>ctDNA is clinically actionable in bladder cancer and prognostic in advanced prostate cancer, whereas ecDNA remains an investigational driver. Structural confirmation of ecDNA in blood, assay standardisation and prospective biomarker-stratified trials are the priorities for the field.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"44 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}